Clinical Study of Umbilical Cord Tissue Mesenchymal Stem... | NCT02237846

Studies
Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis

NCT02237846

Sponsor

Translational Biosciences

Status

Withdrawn

Last Update Posted

Aug 10, 2017Actual

Enrollment

0Actual

Phase

Phase 1Phase 2

Conditions

Osteoarthritis of the Knee

Interventions

Human umbilical cord tissue-derived mesenchymal stem cells

Countries

Panama

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Aug 2017

Overall Recruitment Status or Expanded Access Status

Withdrawn

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

No enrollment

Expanded Access Info

Start Date

Sep 2014

Primary Completion Date

Nov 2018Estimated

Completion Date

Aug 2019Estimated

First Submitted Date

Sep 9, 2014

First Submission Date that Met QC Criteria

Sep 9, 2014

First Posted Date

Sep 11, 2014Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Aug 8, 2017

Last Update Posted Date

Aug 10, 2017Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

Allogeneic human umbilical cord tissue-derived stem cells injected intravenously (IV) once per day for 3 days or once intra-articularly are a safe and will induce a therapeutic effect in osteoarthritis (OA) patients.

Detailed Description

The proposed study will assess primarily safety and secondary efficacy endpoints of allogeneic umbilical cord mesenchymal stem cells (UC-MSC) administered to 40 patients with OA. Arm 1 will receive one intra-articular injection of UC-MSC into the knee and Arm 2 will receive IV UC-MSC once per day for 3 consecutive days.

The primary objective of the trial is freedom from treatment associated adverse events at 3 and 12 months post treatment. Secondary objective will be efficacy as assessed at baseline, and 3 and 12 months post treatment and will be quantified based on the Western Ontario and McMaster osteoarthritis index (WOMAC).

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 1Phase 2

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

0Actual

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Intra-articular knee injection of UC-MSC	Active Comparator	Human umbilical cord tissue-derived mesenchymal stem cells administered into the knee joint once	Biological: Human umbilical cord tissue-derived mesenchymal stem cells
IV injection of UC-MSC	Active Comparator	Human umbilical cord tissue-derived mesenchymal stem cells administered once per day for 3 consecutive days	Biological: Human umbilical cord tissue-derived mesenchymal stem cells

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Human umbilical cord tissue-derived mesenchymal stem cells	Biological		IV injection of UC-MSC Intra-articular knee injection of UC-MSC

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Number of participants with adverse events		3 months and 12 months

Secondary Outcomes

Measure	Description	Time Frame
Number of participants with a change in joint function from baseline WOMAC assessment		3 months and 12 months
Number of participants with a change in radiogrpahic evidence of knee OA from baseline Kellegren-Lawrence grading system		3 months and 12 months

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Signed informed consent by the subject.
Age greater than or equal to 18 years
Ability to understand the planned treatment.
Idiopathic or secondary osteoarthritis of the knee with grade 2, 3, or 4 radiographic severity, as defined by the modified Kellgren-Lawrence classification

Exclusion Criteria:

Pregnant or lactating women
Women of childbearing potential unwilling to use two forms of contraception
Cognitively impaired adults.
Presence of large meniscal tears ("bucket handle" tears), as detected by clinical examination or by magnetic resonance imaging.
Inflammatory or postinfectious arthritis.
More than 5 degrees of varus or valgus deformity.
Kellgren Lawrence grade 4 osteoarthritis in two compartments (the medial or lateral compartments of the tibiofemoral joint or the patellofemoral compartment) in persons over 60 years of age.
Intraarticular corticosteroid injection within the previous 3 months.
A major neurologic deficit.
Serious medical illness with a life expectancy of less than 1 year.
Prior admission for substance abuse
Body Mass Index (BMI) of 40 kg/m2 or greater
Patient receiving experimental medication or participating in another clinical study within 30 days of signing the informed consent
In the opinion of the investigator or the sponsor the patient is unsuitable for cellular therapy

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

80 Years

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

ID	Term
D020370	Osteoarthritis, Knee
D010003	Osteoarthritis

ID	Term
D001168	Arthritis
D007592	Joint Diseases
D009140	Musculoskeletal Diseases
D012216	Rheumatic Diseases